



ELSEVIER

Diabetes Research and Clinical Practice 63 (2004) 231–233

DIABETES RESEARCH  
AND  
CLINICAL PRACTICE

[www.elsevier.com/locate/diabres](http://www.elsevier.com/locate/diabres)

## Author index of volume 63

Abe, E., see Ikarashi, T. **63**, 11

Agarwal, M.M., J. Punnoose, G.S. Dhatt, Gestational diabetes: problems associated with the oral glucose tolerance test **63**, 73

Ahn, J.D., see Park, K.-G. **63**, 135

Aizawa, Y., see Ikarashi, T. **63**, 11

Ajayi, A.A., G.O. Ogungbade, H.C. Hercule, A.O. Oyekan, L. Mutembei, Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA<sub>2</sub> mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats **63**, 155

Aoki, I., see Tanaka, S.-i. **63**, 1

Aragon, F.F., see Pimenta, W.P. **63**, 87

Arroyo, P., see Sánchez-Corona, J. **63**, 47

Aso, K., see Nakazaki, M. **63**, 171

Atsumi, Y., see Suzuki, Y. **63**, 225

Barrera, H., see Sánchez-Corona, J. **63**, 47

Barrett, P.H.R., see Chan, D.C. **63**, 77

Beaven, D.W., see Chen, F. **63**, 113

Bugianesi, E., see Marchesini, G. **63**, 143

Cappleman, J., see Shelmet, J. **63**, 27

Casanueva, F., see Micic, D. **63**, 37

Chan, D.C., G.F. Watts, A.V. Sussekov, P.H.R. Barrett, Z. Yang, J. Hua, S. Song, Adipose tissue compartments and insulin resistance in overweight-obese Caucasian men **63**, 77

Chang, Y.-C., see Park, K.-G. **63**, 135

Chen, F., C.M. Florkowski, M. Dever, D.W. Beaven, Death Certification and New Zealand Health Information Service (NZHIS) statistics for diabetes mellitus: an under-recognised health problem **63**, 113

Chou, P., see Lin, T. **63**, 119

Clifton, P.M., see Morris, A.M. **63**, 179

Cvijovic, G., see Micic, D. **63**, 37

Damm, P., see Stage, E. **63**, 67

Dever, M., see Chen, F. **63**, 113

Dhatt, G.S., see Agarwal, M.M. **63**, 73

Dieguez, C., see Micic, D. **63**, 37

Fernández, V., see Sánchez-Corona, J. **63**, 47

Flores-Martínez, S.E., see Sánchez-Corona, J. **63**, 47

Florkowski, C.M., see Chen, F. **63**, 113

Forlani, G., see Marchesini, G. **63**, 143

Fukudome, M., see Nakazaki, M. **63**, 171

Fukui, M., Y. Kitagawa, N. Nakamura, M. Kadono, S.-i. Mogami, M. Ohnishi, C. Hirata, N. Ichio, K. Wada, C. Kishimoto, H. Okada, H. Miyata, T. Yoshikawa, Idiopathic sudden hearing loss in patients with type 2 diabetes **63**, 205

Fukushige, E., see Nakazaki, M. **63**, 171

Gåfvels, C., see Wändell, P.E. **63**, 195

Galaviz-Hernández, C., see Sánchez-Corona, J. **63**, 47

Gooch, B., see Jovanovic, L. **63**, 127

Greco, S., see Jovanovic, L. **63**, 127

Hale, P.M., see Jovanovic, L. **63**, 127

Hanson, R.L., see Sánchez-Corona, J. **63**, 47

Hanyu, O., see Ikarashi, T. **63**, 11

Hashiguchi, H., see Nakazaki, M. **63**, 171

Hassman, D.R., see Jovanovic, L. **63**, 127

Hercule, H.C., see Ajayi, A.A. **63**, 155

Hirata, C., see Fukui, M. **63**, 205

Hori, M., see Katakami, N. **63**, 93

Hua, J., see Chan, D.C. **63**, 77

Ichio, N., see Fukui, M. **63**, 205

Ikarashi, T., O. Hanyu, S. Maruyama, S. Souda, C. Kobayashi, E. Abe, J. Uki, K. Naganuma, A. Suzuki, M. Toya, S. Kaneko, K. Suzuki, O. Nakagawa, Y. Aizawa, Genotype Gly/Gly of the Arg16Gly polymorphism of the  $\beta_2$ -adrenergic receptor is associated with elevated fasting serum insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic patients, **63**, 11

Ikeda, Y., see Nakazaki, M. **63**, 171

Ishibashi, S., see Yatagai, T. **63**, 19

Ishikawa, S.-e., see Yatagai, T. **63**, 19

Jain, R., see Jovanovic, L. **63**, 127

James, R., see Kerenyi, Z. **63**, 213

Jovanovic, L., D.R. Hassman, B. Gooch, R. Jain, S. Greco, N. Khutoryansky, P.M. Hale, Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone **63**, 127

Kadono, M., see Fukui, M. **63**, 205

Kajimoto, Y., see Katakami, N. **63**, 93

Kamei, J., see Tanaka, S.-i. **63**, 1

Kaneko, S., see Ikarashi, T. **63**, 11

Katakami, N., Y. Yamasaki, K. Kosugi, H. Waki, M. Matsuhisa, Y. Kajimoto, T. Masuyama, M. Hori, Tissue characterization identifies subjects with high risk of cardiovascular diseases **63**, 93

Kato, K., see Nakazaki, M. **63**, 171

Kemp, J., see van de Laar, F.A. **63**, 57

Kendereski, A., see Micic, D. **63**, 37

Kerenyi, Z., H. Samer, R. James, Y. Yan, M. Stewart, Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus **63**, 213

Khutoryansky, N., see Jovanovic, L. **63**, 127

Kim, H.-S., see Park, K.-G. **63**, 135

Kim, M.-J., see Park, K.-G. **63**, 135

Kimura, M., see Tanaka, S.-i. **63**, 1

Kishimoto, C., see Fukui, M. **63**, 205

Kitagawa, Y., see Fukui, M. **63**, 205

Kobayashi, C., see Ikarashi, T. **63**, 11

Koriyama, N., see Nakazaki, M. **63**, 171

Kosugi, K., see Katakami, N. **63**, 93

Kusaka, I., see Yatagai, T. **63**, 19

Laviada-Molina, H.A., see Sánchez-Corona, J. **63**, 47

Lee, I.-K., see Park, K.-G. **63**, 135

Lee, Y.-C., see Lin, T. **63**, 119

Ley, S.J., P.A. Metcalf, R.K.R. Scragg, B.A. Swinburn, Long-term effects of a reduced fat diet intervention on cardiovascular disease risk factors in individuals with glucose intolerance **63**, 103

Liang, J., see Shelmet, J. **63**, 27

Lin, T., P. Chou, S.-T. Tsai, Y.-C. Lee, T.-Y. Tai, Predicting factors associated with costs of diabetic patients in Taiwan **63**, 119

Lucassen, P.L.B.J., see van de Laar, F.A. **63**, 57

Lyness, W., see Shelmet, J. **63**, 27

Lytzen, L., see Shelmet, J. **63**, 27

Machorro-Lazo, M.V., see Sánchez-Corona, J. **63**, 47

Manini, R., see Marchesini, G. **63**, 143

Marchesini, G., E. Bugianesi, G. Forlani, R. Marzocchi, C. Zannoni, E. Vanni, R. Manini, M. Rizzetto, N. Melchionda, Non-alcoholic steatohepatitis in patients cared in metabolic units **63**, 143

Maruyama, S., see Ikarashi, T. **63**, 11

Marzocchi, R., see Marchesini, G. **63**, 143

Masuyama, T., see Katakami, N. **63**, 93

Matsuhisa, M., see Katakami, N. **63**, 93

Matsuo, Y., see Nakanishi, N. **63**, 185

Matsuoka, K., see Suzuki, Y. **63**, 225

Melchionda, N., see Marchesini, G. **63**, 143

Metcalf, P.A., see Ley, S.J. **63**, 103

Micic, D., A. Kendereski, M. Sumarac-Dumanovic, G. Cvijovic, V. Popovic, C. Dieguez, F. Casanueva, Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp **63**, 37

Miyata, H., see Fukui, M. **63**, 205

Mobbs, C., see Tanaka, S.-i. **63**, 1

Mogami, S.-i., see Fukui, M. **63**, 205

Morán-Moguel, M.C., see Sánchez-Corona, J. **63**, 47

Morris, A.M., M. Noakes, P.M. Clifton, In vitro mononuclear cell production of tumour necrosis factor- $\alpha$  and weight loss **63**, 179

Mujica-López, K.I., see Sánchez-Corona, J. **63**, 47

Muramatsu, T., see Suzuki, Y. **63**, 225

Mutembei, L., see Ajayi, A.A. **63**, 155

Naganuma, K., see Ikarashi, T. **63**, 11

Nagasaki, S., see Yatagai, T. **63**, 19

Nakagawa, O., see Ikarashi, T. **63**, 11

Nakamura, N., see Fukui, M. **63**, 205

Nakamura, T., see Yatagai, T. **63**, 19

Nakanishi, N., K. Nishina, M. Okamoto, H. Yoshida, Y. Matsuo, K. Suzuki, K. Tatara, Clustering of components of the metabolic syndrome and risk for development of type 2 diabetes in Japanese male office workers **63**, 185

Nakazaki, M., E. Fukushige, N. Koriyama, M. Fukudome, H. Hashiguchi, K. Aso, J. Yano, Y. Ikeda, K. Kato, C. Tei, Strongest correlation of HbA<sub>1c</sub> with 1-month-earlier glucose levels in type 2 diabetes **63**, 171

Nicklasson, L., see Shelmet, J. **63**, 27

Nishimaki, K., see Suzuki, Y. **63**, 225

Nishina, K., see Nakanishi, N. **63**, 185

Noakes, M., see Morris, A.M. **63**, 179

Ogungbade, G.O., see Ajayi, A.A. **63**, 155

Ohnishi, M., see Fukui, M. **63**, 205

Ohta, S., see Suzuki, Y. **63**, 225

Okada, H., see Fukui, M. **63**, 205

Okamoto, M., see Nakanishi, N. **63**, 185

Okuda, K., see Tanaka, S.-i. **63**, 1

Oyekan, A.O., see Ajayi, A.A. **63**, 155

Padovani, C.R., see Pimenta, W.P. **63**, 87

Pardío, J., see Sánchez-Corona, J. **63**, 47

Park, K.-G., K.S. Park, M.-J. Kim, H.-S. Kim, Y.-S. Suh, J.D. Ahn, K.-K. Park, Y.-C. Chang, I.-K. Lee, Relationship between serum adiponectin and leptin concentrations and body fat distribution **63**, 135

Park, K.-K., see Park, K.-G. **63**, 135

Park, K.S., see Park, K.-G. **63**, 135

Perea, F.J., see Sánchez-Corona, J. **63**, 47

Peterson, G., see Shelmet, J. **63**, 27

Pimenta, W.P., M.V.C. Rudge, F.F. Aragon, C.R. Padovani, Pancreatic  $\beta$ -cell defects in women at risk of type 2 diabetes **63**, 87

Popovic, V., see Micic, D. **63**, 37

Punnoose, J., see Agarwal, M.M. **63**, 73

Rizzetto, M., see Marchesini, G. **63**, 143

Ronneby, H., see Stage, E. **63**, 67

Rudge, M.V.C., see Pimenta, W.P. **63**, 87

Rutten, G.E.H.M., see van de Laar, F.A. **63**, 57

Samer, H., see Kerenyi, Z. **63**, 213

Sánchez-Corona, J., S.E. Flores-Martínez, M.V. Machorro-Lazo, C. Galaviz-Hernández, M.C. Morán-Moguel, F.J. Perea, K.I. Mujica-López, L. Vargas-Ancona, H.A. Laviada-Molina, V. Fernández, J. Pardío, P. Arroya, H. Barrera, R.L. Hanson, Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings **63**, 47

Schwartz, S., see Shelmet, J. **63**, 27

Scragg, R.K.R., see Ley, S.J. **63**, 103

Shelmet, J., S. Schwartz, J. Cappleman, G. Peterson, S. Skovlund, L. Lytzen, L. Nicklasson, J. Liang, W. Lyness, Preference and resource utilization in elderly patients: InnoLet® versus vial/syringe **63**, 27

Skovlund, S., see Shelmet, J. **63**, 27

Song, S., see Chan, D.C. **63**, 77

Souda, S., see Ikarashi, T. **63**, 11

Stage, E., H. Ronneby, P. Damm, Lifestyle change after gestational diabetes **63**, 67

Stewart, M., see Kerenyi, Z. **63**, 213

Suh, Y.-S., see Park, K.-G. **63**, 135

Sumarac-Dumanovic, M., see Micic, D. **63**, 37

Sussekov, A.V., see Chan, D.C. **63**, 77

Suzuki, A., see Ikarashi, T. **63**, 11

Suzuki, K., see Ikarashi, T. **63**, 11

Suzuki, K., see Nakanishi, N. **63**, 185

Suzuki, Y., K. Nishimaki, M. Taniyama, T. Muramatsu, Y. Atsumi, K. Matsuoka, S. Ohta, Lipoma and ophthalmoplegia in mitochondrial diabetes associated with small heteroplasmy level of 3243 tRNA<sup>Leu(UUR)</sup> mutation **63**, 225

Swinburn, B.A., see Ley, S.J. **63**, 103

Tai, T.-Y., see Lin, T. **63**, 119

Tanaka, S.-i., T. Yamakawa, M. Kimura, I. Aoki, J. Kamei, K. Okuda, C. Mobbs, Daily nasal inoculation with the insulin gene ameliorates diabetes in mice **63**, 1

Taniyama, M., see Suzuki, Y. **63**, 225

Tatara, K., see Nakanishi, N. **63**, 185

Tei, C., see Nakazaki, M. **63**, 171

Toya, M., see Ikarashi, T. **63**, 11

Tsai, S.-T., see Lin, T. **63**, 119

Ukisu, J., see Ikarashi, T. **63**, 11

van de Laar, F.A., P.L.B.J. Lucassen, J. Kemp, E.H. van de Lisdonk, C. van Weel, G.E.H.M. Rutten, Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial **63**, 57

van de Lisdonk, E.H., see van de Laar, F.A. **63**, 57

van Weel, C., see van de Laar, F.A. **63**, 57

Vanni, E., see Marchesini, G. **63**, 143

Vargas-Ancona, L., see Sánchez-Corona, J. **63**, 47

Wada, K., see Fukui, M. **63**, 205

Waki, H., see Katakami, N. **63**, 93

Wändell, P.E., C. Gåfvels, Patients with type 2 diabetes aged 35–64 years at four primary health care centres in Stockholm County, Sweden. Prevalence and complications in relation to gender and socio-economic status **63**, 195

Watts, G.F., see Chan, D.C. **63**, 77

Yamakawa, T., see Tanaka, S.-i. **63**, 1

Yamasaki, Y., see Katakami, N. **63**, 93

Yan, Y., see Kerenyi, Z. **63**, 213

Yang, Z., see Chan, D.C. **63**, 77

Yano, J., see Nakazaki, M. **63**, 171

Yatagai, T., T. Nakamura, S. Nagasaka, I. Kusaka, S.-e. Ishikawa, A. Yoshitaka, S. Ishibashi, Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects **63**, 19

Yoshida, H., see Nakanishi, N. **63**, 185

Yoshikawa, T., see Fukui, M. **63**, 205

Yoshitaka, A., see Yatagai, T. **63**, 19

Zannoni, C., see Marchesini, G. **63**, 143





## Subject index of volume 63

**β<sub>2</sub>-Adrenergic receptor**; Genetic polymorphism; Type 2 diabetes mellitus; Insulin secretion **63**, 11

**Adiponectin**; Leptin; Visceral adipose tissue; Subcutaneous adipose tissue; Obesity **63**, 135

**Atherosclerosis**; Cardiovascular diseases; Carotid artery; Tissue characterization; Integrated backscatter **63**, 93

**Blood pressure**; Glucose intolerance; Reduced fat diet; Cardiovascular disease risk factors; Cholesterol **63**, 103

**C-reactive protein**; Troglitazone; Metformin; Insulin resistance **63**, 19

**Candidate genes**; Metabolic syndrome; Genetics; Type 2 diabetes mellitus; Insulin **63**, 47

**Cardiovascular disease risk factors**; Glucose intolerance; Reduced fat diet; Cholesterol; Blood pressure **63**, 103

**Cardiovascular disease**; Visceral obesity; Humans; Metabolic syndrome; Insulin resistance **63**, 77

**Cardiovascular diseases**; Atherosclerosis; Carotid artery; Tissue characterization; Integrated backscatter **63**, 93

**Carotid artery**; Cardiovascular diseases; Atherosclerosis; Tissue characterization; Integrated backscatter **63**, 93

**Cholesterol**; Glucose intolerance; Reduced fat diet; Cardiovascular disease risk factors; Blood pressure **63**, 103

**Clinical coding**; Mortality; Death certificates; Diabetes mellitus **63**, 113

**Cluster**; Type 2 diabetes; Metabolic syndrome; Longitudinal study; Japanese men **63**, 185

**Combination therapy**; Insulin secretagogues; Thiazolidinedione; OAD monotherapy failure **63**, 127

**Combination therapy**; Rosiglitazone; Glibenclamide; Thiazolidinediones; Sulphonylureas **63**, 213

**Costs**; Diabetes; Predicting factors **63**, 119

**Death certificates**; Mortality; Clinical coding; Diabetes mellitus **63**, 113

**Diabetes mellitus**; Gene transfer; Nasal administration; Liposome **63**, 1

**Diabetes mellitus**; Mortality; Death certificates; Clinical coding **63**, 113

**Diabetes mellitus**; Primary health care; Gender; Socio-economic status; Sweden **63**, 195

**Diabetes, non-insulin dependent**; Obesity; Hyperlipidemia; Fatty liver; Metabolic syndrome X **63**, 143

**Diabetes**; Costs; Predicting factors **63**, 119

**Endothelin receptors**; Type-2 diabetes; Zucker rats; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155

**Endothelin-B receptor antagonists**; Type-2 diabetes; Zucker rats; Endothelin receptors; Thromboxanes; Endothelin-B receptor antagonists **63**, 155

**Endotheliopathy**; Type-2 diabetes; Zucker rats; Endothelin receptors; Thromboxanes; Endothelin-B receptor antagonists **63**, 155

**Euglycemic clamp**; Growth hormone; GHRH + GHRP-6; Hyperglycemic clamp; Type 2 diabetes **63**, 37

**Fatty liver**; Diabetes, non-insulin dependent; Obesity; Hyperlipidemia; Metabolic syndrome X **63**, 143

**Gender;** Diabetes mellitus; Primary health care; Socio-economic status; Sweden **63**, 195

**Gene transfer;** Diabetes mellitus; Nasal administration; Liposome **63**, 1

**General practice;** Sulphonylurea;  $\alpha$ -Glucosidase inhibitor; The Netherlands **63**, 57

**Genetic polymorphism;**  $\beta_2$ -Adrenergic receptor; Type 2 diabetes mellitus; Insulin secretion **63**, 11

**Genetics;** Metabolic syndrome; Type 2 diabetes mellitus; Candidate genes; Insulin **63**, 47

**Gestational diabetes;** Oral glucose tolerance test; Limitations **63**, 73

**Gestational hyperglycemia;** Insulin release; Insulin sensitivity; Type 2 diabetes **63**, 87

**GHRH + GHRP-6;** Growth hormone; Euglycemic clamp; Hyperglycemic clamp; Type 2 diabetes **63**, 37

**Glibenclamide;** Rosiglitazone; Thiazolidinediones; Combination therapy; Sulphonylureas **63**, 213

**$\alpha$ -Glucosidase inhibitor;** General practice; Sulphonylurea; The Netherlands **63**, 57

**Glucose intolerance;** Reduced fat diet; Cardiovascular disease risk factors; Cholesterol; Blood pressure **63**, 103

**Growth hormone;** GHRH + GHRP-6; Euglycemic clamp; Hyperglycemic clamp; Type 2 diabetes **63**, 37

**HbA<sub>1c</sub> and plasma glucose;** Type 2 diabetes mellitus; Outpatient **63**, 171

**Healthcare costs;** Insulin delivery systems; Quality of life; Patient independence; Patient acceptance **63**, 27

**Humans;** Visceral obesity; Metabolic syndrome; Insulin resistance; Cardiovascular disease **63**, 77

**Hyperglycemic clamp;** Growth hormone; GHRH + GHRP-6; Euglycemic clamp; Type 2 diabetes **63**, 37

**Hyperlipidemia;** Diabetes, non-insulin dependent; Obesity; Fatty liver; Metabolic syndrome X **63**, 143

**Idiopathic sudden hearing loss;** Type 2 diabetes; Severity of hearing loss **63**, 205

**Insulin delivery systems;** Healthcare costs; Quality of life; Patient independence; Patient acceptance **63**, 27

**Insulin release;** Gestational hyperglycemia; Insulin sensitivity; Type 2 diabetes **63**, 87

**Insulin resistance;** Troglitazone; Metformin; C-reactive protein **63**, 19

**Insulin resistance;** Visceral obesity; Humans; Metabolic syndrome; Cardiovascular disease **63**, 77

**Insulin secretagogues;** Thiazolidinedione; Combination therapy; OAD monotherapy failure **63**, 127

**Insulin secretion;**  $\beta_2$ -Adrenergic receptor; Genetic polymorphism; Type 2 diabetes mellitus **63**, 11

**Insulin sensitivity;** Gestational hyperglycemia; Insulin release; Type 2 diabetes **63**, 87

**Insulin;** Metabolic syndrome; Genetics; Type 2 diabetes mellitus; Candidate genes **63**, 47

**Integrated backscatter;** Cardiovascular diseases; Atherosclerosis; Carotid artery; Tissue characterization **63**, 93

**Japanese men;** Type 2 diabetes; Metabolic syndrome; Cluster; Longitudinal study **63**, 185

**Leptin;** Adiponectin; Visceral adipose tissue; Subcutaneous adipose tissue; Obesity **63**, 135

**Lifestyle;** Previous gestational diabetes **63**, 67

**Limitations;** Gestational diabetes; Oral glucose tolerance test **63**, 73

**Lipoma;** Oculomotor palsy; 3243 mitochondrial DNA mutation; Mitochondrial diabetes **63**, 225

**Liposome;** Diabetes mellitus; Gene transfer; Nasal administration **63**, 1

**Longitudinal study;** Type 2 diabetes; Metabolic syndrome; Cluster; Japanese men **63**, 185

**Metabolic syndrome X;** Diabetes, non-insulin dependent; Obesity; Hyperlipidemia; Fatty liver **63**, 143

**Metabolic syndrome;** Genetics; Type 2 diabetes mellitus; Candidate genes; Insulin **63**, 47

**Metabolic syndrome;** Type 2 diabetes; Cluster; Longitudinal study; Japanese men **63**, 185

**Metabolic syndrome;** Visceral obesity; Humans; Insulin resistance; Cardiovascular disease **63**, 77

**Metformin;** Troglitazone; C-reactive protein; Insulin resistance **63**, 19

**Mitochondrial diabetes;** Lipoma; Oculomotor palsy; 3243 mitochondrial DNA mutation **63**, 225

**3243 mitochondrial DNA mutation;** Lipoma; Oculomotor palsy; Mitochondrial diabetes **63**, 225

**Mononuclear cell;** Obesity; TNF- $\alpha$ ; Weight loss; Type 2 diabetes **63**, 179

**Mortality;** Death certificates; Clinical coding; Diabetes mellitus **63**, 113

**Nasal administration;** Diabetes mellitus; Gene transfer; Liposome **63**, 1

**OAD monotherapy failure;** Insulin secretagogues; Thiazolidinedione; Combination therapy **63**, 127

**Obesity;** Adiponectin; Leptin; Visceral adipose tissue; Subcutaneous adipose tissue **63**, 135

**Obesity;** Diabetes, non-insulin dependent; Hyperlipidemia; Fatty liver; Metabolic syndrome X **63**, 143

**Obesity;** TNF- $\alpha$ ; Weight loss; Type 2 diabetes; Mononuclear cell **63**, 179

**Oculomotor palsy;** Lipoma; 3243 mitochondrial DNA mutation; Mitochondrial diabetes **63**, 225

**Oral glucose tolerance test;** Gestational diabetes; Limitations **63**, 73

**Outpatient;** Type 2 diabetes mellitus; HbA<sub>1c</sub> and plasma glucose **63**, 171

**Patient acceptance;** Insulin delivery systems; Healthcare costs; Quality of life; Patient independence **63**, 27

**Patient independence;** Insulin delivery systems; Healthcare costs; Quality of life; Patient acceptance **63**, 27

**Predicting factors;** Diabetes; Costs **63**, 119

**Previous gestational diabetes;** Lifestyle **63**, 67

**Primary health care;** Diabetes mellitus; Gender; Socio-economic status; Sweden **63**, 195

**Quality of life;** Insulin delivery systems; Healthcare costs; Patient independence; Patient acceptance **63**, 27

**Reduced fat diet;** Glucose intolerance; Cardiovascular disease risk factors; Cholesterol; Blood pressure **63**, 103

**Rosiglitazone;** Glibenclamide; Thiazolidinediones; Combination therapy; Sulphonylureas **63**, 213

**Severity of hearing loss;** Type 2 diabetes; Idiopathic sudden hearing loss **63**, 205

**Socio-economic status;** Diabetes mellitus; Primary health care; Gender; Sweden **63**, 195

**Subcutaneous adipose tissue;** Adiponectin; Leptin; Visceral adipose tissue; Obesity **63**, 135

**Sulphonylurea;** General practice;  $\alpha$ -Glucosidase inhibitor; The Netherlands **63**, 57

**Sulphonylureas;** Rosiglitazone; Glibenclamide; Thiazolidinediones; Combination therapy **63**, 213

**Sweden;** Diabetes mellitus; Primary health care; Gender; Socio-economic status **63**, 195

**The Netherlands;** General practice; Sulphonylurea;  $\alpha$ -Glucosidase inhibitor **63**, 57

**Thiazolidinedione;** Insulin secretagogues; Combination therapy; OAD monotherapy failure **63**, 127

**Thiazolidinediones;** Rosiglitazone; Glibenclamide; Combination therapy; Sulphonylureas **63**, 213

**Thromboxanes;** Type-2 diabetes; Zucker rats; Endothelin receptors; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155

**Tissue characterization;** Cardiovascular diseases; Atherosclerosis; Carotid artery; Integrated backscatter **63**, 93

**TNF- $\alpha$** ; Obesity; Weight loss; Type 2 diabetes; Mononuclear cell **63**, 179

**Troglitazone**; Metformin; C-reactive protein; Insulin resistance **63**, 19

**Type 2 diabetes mellitus**;  $\beta_2$ -Adrenergic receptor; Genetic polymorphism; Insulin secretion **63**, 11

**Type 2 diabetes mellitus**; Metabolic syndrome; Genetics; Candidate genes; Insulin **63**, 47

**Type 2 diabetes mellitus**; Outpatient; HbA<sub>1c</sub> and plasma glucose **63**, 171

**Type 2 diabetes**; Gestational hyperglycemia; Insulin release; Insulin sensitivity **63**, 87

**Type 2 diabetes**; Growth hormone; GHRH + GHRP-6; Euglycemic clamp; Hyperglycemic clamp **63**, 37

**Type 2 diabetes**; Idiopathic sudden hearing loss; Severity of hearing loss **63**, 205

**Type 2 diabetes**; Metabolic syndrome; Cluster; Longitudinal study; Japanese men **63**, 185

**Type 2 diabetes**; Obesity; TNF- $\alpha$ ; Weight loss; Mononuclear cell **63**, 179

**Type-2 diabetes**; Zucker rats; Endothelin receptors; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155

**Visceral adipose tissue**; Adiponectin; Leptin; Subcutaneous adipose tissue; Obesity **63**, 135

**Visceral obesity**; Humans; Metabolic syndrome; Insulin resistance; Cardiovascular disease **63**, 77

**Weight loss**; Obesity; TNF- $\alpha$ ; Type 2 diabetes; Mononuclear cell **63**, 179

**Zucker rats**; Type-2 diabetes; Endothelin receptors; Thromboxanes; Endotheliopathy; Endothelin-B receptor antagonists **63**, 155